Impact of safety-related regulatory action on clinical practice: A systematic review

Drug Safety

Volumn 35, Issue 5, 2012, Pages 373-385

  Piening, Sigrid ^a   Haaijer Ruskamp, Flora M ^a   De Vries, Jonie T N ^a   Van Der Elst, Menno E ^b   De Graeff, Pieter A ^a,b   Straus, Sabine M J M ^b,c   Mol, Peter G M ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cisapride; Oral contraceptives; Regulatory process; Serotonin uptake inhibitors

Indexed keywords

ORAL CONTRACEPTIVE AGENT; SEROTONIN UPTAKE INHIBITOR;

BLACK BOX WARNINGS; CLINICAL PRACTICE; DATA ANALYSIS; DIRECT HEALTHCARE PROFESSIONAL COMMUNICATION; DRUG LABELING; DRUG SAFETY; HEALTH CARE PERSONNEL; HUMAN; MASS COMMUNICATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLIC HEALTH ADVISORY; REVIEW; STUDY DESIGN; SYSTEMATIC REVIEW;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COMMUNICATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LEGISLATION, DRUG; PAMPHLETS; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84859898969     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11599100-000000000-00000     Document Type: Review

References (72)

1. Califf RM. Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics. Pharmacoepidemiol Drug Saf 2007; 16 (1): 5-16
2. Stricker BC, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004 07; 329 (7456): 44-7
3. Mol PGM, Straus SMJM, Piening S, et al. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from1999 to 2009.Drug Saf 2010; 33 (6): 463-74
4. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002 05; 287 (17): 2215-20
5. Heemstra HE, Giezen TJ, Mantel-Teeuwisse AK, et al. Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study. Drug Saf 2010; 33 (2): 127-37
6. Hawkey CJ, LangmanMJS.Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 2003; 52 (4): 600-8
7. Graham DJ, Ouellet-Hellstrom R, Macurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010 07; 304 (4): 411-8
8. Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008 10; 300 (16): 1887-96
9. Woosley RL. Drug labeling revisions: guaranteed to fail? JAMA 2000 12; 284 (23): 3047-9
10. Goldman SA. Communication of medical product risk: how effective is effective enough? Drug Saf 2004; 27 (8): 519-34
11. Murray ML, Thompson M, Santosh PJ, et al. Effects of the committee on safety of medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Saf 2005; 28 (12): 1151-7
12. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164 (9): 1356-63
13. Valuck RJ, Libby AM, Orton HD, et al. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidally with SSRIs. Am J Psychiatry 2007; 164 (8): 1198-205
14. Olfson M, Marcus SC, Druss BG. Effects of food and drug administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008; 65 (1): 94-101
15. Wheeler BW, Gunnell D, Metcalfe C, et al. The population impact on incidence of suicide and non-fatal self harm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological study. BMJ 2008 03; 336 (7643): 542-5
16. The European Parliament and the European Council. Regulation (EU) no. 1235/2 2010 [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do? uri=OJ:L:2010:348:0001:0016:EN:PDF [Accessed 2010 Jan 4]
17. The European Parliament and the European Council. Directive 2010/84/EU. 2010 [online].Available fromURL: http://eur-lex. europa.eu/LexUriServ/ LexUriServ.do?uri=OJ:L:2010:348: 0074:0099:EN:PDF [Accessed 2011 Jan 4]
18. Ramsay CR, Matowe L, Grilli R, et al. Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies. Int J Technol Assess Health Care 2003; 19 (4): 613-23
19. National Health Service Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRDs guidance for carrying out or commissioning reviews. 2nd ed. CRD Report York: University of York, 2001
20. Cochrane Effective Practice and Organisation ofCareReview Group. The data collection checklist [online]. Available from URL: http://epoc.cochrane.org/ sites/epoc.cochrane.org/files/uploads/datacollectionchecklist.pdf [Accessed 2011 Apr 13]
21. Wilkinson JJ, Force RW, Cady PS. Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone. Pharmacotherapy 2004; 24 (8): 978-86
22. Starner CI, Schafer JA, Heaton AH, et al. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Managed Care Pharm 2008; 14 (6): 523-31
23. Guo JJ, Curkendall S, Jones JK, et al. Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiol Drug Saf 2003; 12 (4): 295-301
24. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000 12; 284 (23): 3036-9
25. Jones JK, Fife D, Curkendall S, et al. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 2001 10; 286 (13): 1607-9
26. Weatherby LB, Walker AM, Fife D, et al. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of Dear Doctor letters. Pharmacoepidemiol Drug Saf 2001; 10 (3): 211-8
27. Kurian BT, Ray WA, Arbogast PG, et al. Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch Pediatr Adolesc Med 2007; 161 (7): 690-6
28. Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 2007; 64 (4): 466-72
29. Forrester MB. Selective serotonin re-uptake inhibitor warnings and trends in exposures reported to poison control centres in Texas. Public Health 2008; 122 (12): 1356-62
30. Morrato EH, Libby AM, Orton HD, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2008; 165 (1): 42-50
31. Singh T, Prakash A, Rais T, et al. Decreased use of antidepressants in youth after US Food and Drug Administration black box warning. Psychiatry (USA) 2009; 6 (10): 30-4
32. Carlson AM, Stockwell Morris L. Coprescription of terfenadine and erythromycin or ketoconazole: an assessment of potential harm. J Am Pharm Assoc 1996 36 4 263-9
33. Thompson D, Oster G. Use of terfenadine and contraindicated drugs. JAMA 1996 05; 275 (17): 1339-41
34. Burkhart GA, Sevka MJ, Temple R, et al. Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin. Clin Pharmacol Ther 1997; 61 (1): 93-6
35. Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001 08; 286 (7): 831-3
36. Cluxton Jr RJ, Li Z, Heaton PC, et al. Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program. Pharmacoepidemiol Drug Saf 2005; 14 (1): 1-9
37. Shatin D, Gardner JS, Stergachis A, et al. Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants. Pharmacoepidemiol Drug Saf 2005; 14 (3): 149-54
38. Shatin D, Rawson NSB, Curtis JR, et al. Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions. Pharmacoepidemiol Drug Saf 2006; 15 (1): 11-8
39. Willy ME, Manda B, Shatin D, et al. A study of compliance with FDA recommendations for pemoline (Cylert-). J Am Acad Child Adolesc Psychiatry 2002; 41 (7): 785-90
40. Gleason PP, Walters C, Heaton AH, et al. Telithromycin: the perils of hasty adoption and persistence of off-label prescribing. J Managed Care Pharm 2007; 13 (5): 420-5
41. Kazmierczak R, Coley KC. Impact of Dear Doctor letters on prescribing: evaluation of the use of tramadol HCl. Formulary 1997; 32 (9): 968-78
42. Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. AmJ Psychiatry 2007; 164 (6): 884-91
43. Child TJ, Mackenzie IZ, Rees M. Terminations of pregnancy, not unplanned deliveries, increased as result of pill scare [letter]. BMJ 1996; 313 (7063): 1005
44. Ferguson JJ, Jenkins MGV, Murty J, et al. Effect of CSMs warning about safety of third generation oral contraceptives. BMJ 1996; 313 (7053): 363-4
45. Martin RM, Hilton SR, Kerry SM. The impact of the October 1995 pill scare on oral contraceptive use in the United Kingdom: analysis of a general practice automated database. Fam Pract 1997; 14 (4): 279-84
46. Roberts SJ. The immediate effects of the pill safety scare on usage of combined oral contraceptives in north east England. J Epidemiol Community Health 1997; 51 (3): 332-3
47. Wood R, Botting B, Dunnell K. Trends in conceptions before and after the 1995 pill scare. Popul Trends 1997; (89): 5-12
48. Farmer RDT, Williams TJ, Simpson EL, et al. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of General Practice Research Database. BMJ 2000 08; 321 (7259): 477-9
49. Skjeldestad FE. Increased number of induced abortions in Norway after media coverage of adverse vascular events from the use of third-generation oral contraceptives. Contraception 1997; 55 (1): 11-4
50. Williams D, Kelly A, Carvalho M, et al. Effect of the British warning on contraceptive use in the General Medical Service in Ireland. Ir Med J 1998; 91 (6): 202-3
51. De Vries CS, Van Den Berg PB, De Jong-Van Den Berg LTW. Oral contraceptive use before and after the latest pill scare in the Netherlands: changes in oral contraceptive use and how users change. Contraception 1998; 57 (4): 247-9
52. Raschetti R, Maggini M, Da Cas R, et al. Time trends in the coprescribing of cisapride and contraindicated drugs in Umbria, Italy. JAMA 2001 04; 285 (14): 1840-1
53. Staniscia T, Romano F, Festi D, et al. Co-dispensing of contraindicated medications in patients using cisapride in Italy. Pharmacoepidemiol Drug Saf 2006 07; 15 (7): 469-76
54. De Bruin ML, Panneman MJM, Leufkens HGM, et al. Use of cisapride with contraindicated drugs in the Netherlands. Ann Pharmacother 2002; 36 (2): 338-43
55. Bergen H, Hawton K, Murphy E, et al. Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under- 18-year-olds. Br J Clin Pharmacol 2009; 68 (4): 618-29
56. Wheeler BW, Metcalfe C, Gunnell D, et al. Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological study. Br J Clin Pharmacol 2009; 68 (5): 752-64
57. Malgarini RB, Pimpinella G. Thrombotic thrombocytopenic purpura induced by ticlopidine: the power of Dear Health Professional letters. Ann Pharmacother 2000; 34 (3): 404-5
58. Motola D, Vargiu A, Leone R, et al. Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. Drug Saf 2008; 31 (7): 609-16
59. Morera T, Gervasini G, Carrillo JA, et al. Evaluation of a drug-drug interaction alert structure through the retrospective analysis of statins-macrolides co-prescriptions. Basic Clin Pharmacol Toxicol 2005; 96 (4): 289-94
60. De la Porte M, Reith D, Tilyard M. Impact of safety alerts upon prescribing of cisapride to children in New Zealand. N Z Med J 2002; 115 (1157): 1-9
61. Katz LY, Kozyrskyj AL, Prior HJ, et al. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ 2008; 178 (8): 1005-11
62. Kurdyak PA, Juurlink DN, Mamdani MM. The effect of antidepressant warnings on prescribing trends in Ontario, Canada. Am J Public Health 2007; 97 (4): 750-4
63. Dean AJ, Hendy A, McGuire T. Antidepressants in children and adolescents: changes in utilization after safety warnings. Pharmacoepidemiol Drug Saf 2007; 16 (9): 1048-53
64. Valiyeva E, Herrmann N, Rochon PA, et al. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ 2008 08; 179 (5): 438-46
65. Azoulay L, Oraichi D, Berard A. Patterns and utilization of isotretinoin for acne from 1984 to 2003: is there need for concern? Eur J Clin Pharmacol 2006 08; 62 (8): 667-74
66. Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 2009; 66 (6): 633-9
67. Panorama. The secrets of seroxat. BBC News [online]. Available from URL: http://news.bbc.co.uk/2/hi/programmes/ panorama/2310197.stm [Accessed 2011 Feb 10]
68. US Food and Drug Administration. Historical information on antidepressant use in children, adolescents, and adults [online]. Available from URL: http://www.fda.gov/Drugs/ DrugSafety/InformationbyDrugClass/ucm096293.htm [Accessed 2011 Feb 15]
69. Berry DC, Raynor DK, Knapp P, et al. Official warnings on thromboembolism risk with oral contraceptives fail to inform users adequately. Contraception 2002 11; 66 (5): 305-7
70. Ramsay C, Brown E, Hartman G, et al. Room for improvement: a systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing. J Antimicrob Chemother 2003; 52 (5): 764-71
71. Lu CY, Ross-Degnan D, Soumerai SB, et al. Interventions to improve the quality and efficiency of medication use in managed care: a critical review of the literature 2001-2007. BMC Health Serv Res 2008; 8: 75-86
72. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27 (4): 299-309